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Abstract  
Objective 
To review the evidence for the efficacy and safety of colchicine in children with pericarditis.  
 
Design 
Systematic review 
 
Search strategy 
The following databases were searched for studies about colchicine in children with pericarditis 
(June 2015): Cochrane Central, Medline, EMBASE and LILACS.  
 
Eligibility criteria 
All observational and experimental studies on humans with any length of follow-up and no 
limitations on language or publication status were included. The outcomes studied were 
recurrences of pericarditis and adverse events. 
 
Data extraction 
Two authors extracted data and assessed quality of included studies using the Cochrane risk of 
bias tool for non-randomized trials. 
 
Results 
Two case series and nine case reports reported the use of colchicine in a total of 86 children with 
pericarditis. Five articles including 74 paediatric patients were in favour of colchicine in 
preventing further pericarditis recurrences. Six studies including 12 patients showed that 
colchicine did not prevent recurrences of pericarditis.  
 
Limitations 
No randomised controlled trials were found. 
 
Conclusion 
Although colchicine is an established treatment for pericarditis in adults, it is not routinely used 
in children. There is not enough evidence to support or discourage the use of colchicine in 
children with pericarditis. Further research in the form of large double-blind randomised 
controlled trials is needed to establish the efficacy of colchicine in children with pericarditis. 
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INTRODUCTION 
Pericarditis is the inflammation of the pericardium, the membranous sac surrounding the heart. 
Pericarditis is idiopathic in 80% of cases, however it is presumed to be viral in origin 1. Other 
causes of pericarditis include post-pericardiotomy syndrome, tuberculosis or bacterial and 
neoplastic diseases 2. Post-pericardiotomy syndrome is a more common cause in children than in 
adults 3. 
The incidence of pericarditis is 2-3 in every 1000 hospitalised children 4. Symptoms include 
chest pain and fever which can present as recurrent episodes in up to 15% - 30%. Recurrent 
pericarditis severely impairs quality of life and can be disabling5. 
The diagnosis of pericarditis can be challenging. The most common signs include a pericardial 
rub or effusion1 and electrocardiography (ECG) changes such a widespread ST-segment 
elevation might be present. Raised inflammatory markers such as erythrocyte sedimentation rate 
(ESR) or C-reactive protein (CRP) with chest pain might be the only signs1.  
Colchicine has been shown to be effective in preventing recurrent episodes in adults 6±9, however 
it is not routinely used in children 10. The objective of this systematic review was to identify the 
efficacy and safety of colchicine in children. 
METHODS 
This systematic review was registered in the international database of prospectively registered 
systematic reviews in health and social care (PROSPERO) on the 20th July 2015 (registration 
number: CRD42015024647) 11. 
Data Sources 
The following databases were searched (from their start to June 2015): Cochrane Central, 
Medline, EMBASE and LILACS. The search did not include any language or time restriction. 
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The search strategy was designed for maximum sensitivity using the Boolean operator AND to 
combine all synonyms for colchicine with all possible ways of referring to pericarditis. (See 
appendix 1 for full details.) In addition, bibliographic references of identified articles were 
reviewed. We searched www.clinicaltrials.gov for on-going trials on 14th February 2016. 
Eligibility Criteria 
Although randomised controlled trials (RCT) are the best way to test treatments, we anticipated 
that we would not find many. Therefore our eligibility criteria were any study design of 
pericarditis in children treated with colchicine. There was no limitation on length of follow-up, 
language or publication status. 
Outcomes 
1) Efficacy of colchicine in treating children with pericarditis, defined as prevention of 
recurrences or symptom relief. 
2) Adverse effects and tolerability of colchicine in children. 
Data extraction and analysis 
Two authors independently screened titles and abstracts for inclusion. The opinion of a third 
author was sought when an agreement could not be reached. Full-text publications were obtained 
for included studies or where eligibility was unclear from the title and abstract. Two authors 
extracted data and assessed quality of included studies using a pre-defined data collection form.  
We adopted the Cochrane risk of bias tool for non-randomized trials (ACROBAT-NRSI) to 
assess the quality of included studies 12. The tool assesses domains of confounding, selection of 
participants, outcome measurement, missing data and follow-up. 
Subgroup analysis 
We planned to analyse dose regimens used and duration of treatment.  
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RESULTS 
A total of 352 records were identified. Removal of duplicates left 266 articles for screening. A 
total of 68 full texts were assessed for eligibility and 11 articles met the inclusion criteria 
(Figure 1). No additonal study was found through the manual search of bibliographic references 
of the retrieved papers. No ongoing clinical trials were found on clinicaltrials.gov. 
Study Characteristics 
Two case series 13,14 and nine case reports 4,15±19 reported the use of colchicine in a total of 86 
children with pericarditis.  
Studies reported children with different severities of pericarditis. Three studies (two case 
reports and one case series) were in children with post-pericardiotomy syndrome 13,20,21.  
The study characteristics are given in table 1.  
 
Quality of included studies 
1) Selection of participants  
Two case series were included. Consecutive inclusion of patients was reported in one of the 
studies 14, while we could not tell if all consecutively patients were included in the other case 
series 13.  
2) Risk of bias of confounding. 
No included study pre-specified a list of potential confounders of pericarditis therapy. No study 
carried out statistical modelling for confounding factors or adjusted for time-varying 
confounding. 
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We could not tell from the included reports if confounding factors such as indication of 
treatment, additional therapies, type of pericarditis and age of children, affected the effect of 
colchicine. 
3) Outcome measurement and assessment 
Methods for collecting data were poorly reported and we could not tell if any of the studies 
used more than one outcome assessor to repeat the analysis to ensure reliability. 
None of the included studies had control groups. Findings were reported as recurrence free 
period after colchicine. Two studies reported pre- and post- colchicine recurrence rate 13,14.  
4) Missing data 
The included papers did not report incomplete or missing data. We could not tell if this because 
of lack or reporting or absence of missing data. However, the included case reports had 
appropriate follow up of 6 ± 24 months (Table 1).  
Two articles were only available as conference abstracts 14,17 which limited the amount of data 
available.  
 
Efficacy of colchicine or pericarditis in children 
Included studies were heterogeneous in populations, study designs and outcome reporting; we 
therefore did not pool data in a meta-analysis. The findings of the included studies are described 
below. Two types of pericarditis were studied: idiopathic pericarditis and post-pericardiotomy 
syndrome.  
A detailed data extraction of all included studies is given in Appendix 2. 
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Idiopathic Pericarditis 
Seven case reports 4,15±19,22 and one case series 14 reported the use of colchicine in children with 
idiopathic pericarditis. 
The case reports included 12 children with a median age of 11.5 (range 2-14) and 70% male 
gender distribution. All children had multiple recurrences of pericarditis while treated with 
NSAIDs and steroids. When colchicine was added, 7 out of 12 children (58%) had no further 
recurrences, while the other 5 (42%) continued to have recurrences. The median follow up was 
12 months (range 6 ± 60). The included articles did not report the exact number of pericarditis 
recurrences pre and post colchicine treatment. 
The case series was only available as an abstract and included 100 children with a median age of 
13 (range 1 ± 17) and 62% male gender distribution. Colchicine was added to NSAIDs or 
steroids in 67 patients (67%). The median follow up was 60 months (range 6 ± 360 months). The 
number of pericarditis recurrences per year was 3.8 before colchicine was given and 1.6 
afterwards. 
 
Post-pericardiotomy syndrome 
One case series 13 and two case reports 20,21 reported the use of colchicine in children with post-
pericardiotomy syndrome. 
The case series studied 15 children with at least two recurrences of pericarditis post open heart 
surgery. Four patients were treated with NSAIDs and eleven with steroids. Colchicine was added 
to four patients on steroid treatment. The four patients on colchicine had a median age of 12.5 
years (range 8 to 16 years). All children treated with colchicine had further recurrences of 
pericarditis. The mean number of recurrence while on steroids only was 2.4 recurrences per year 
and increased to 4.8 recurrences per year after colchicine was started. The mean number of 
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recurrences in the NSAIDs group were 1.2 recurrences per year. The authors concluded that 
colchicine was not effective in preventing pericarditis recurrences. However, colchicine was only 
used in the more severe steroid-resistant group. 
 
The two case reports included 3 children, one girl aged 4 and two boys aged 4 and 12. The 
children had recurrent episodes of pericarditis following cardiac surgery. The pericarditis 
episodes were not controlled with NSAIDs or steroids.  The three children continued to have 
recurrences during their 24 months follow up after colchicine was added. 
Adverse effects of colchicine in children 
Severe adverse events were not reported in the included studies. Adverse effects included   
abdominal symptoms such as nausea and diarrhoea 4,17,23.  
Colchicine dose and treatment regime 
Yaazigi 1998 and Del Fresno 2013 used a colchicine dose of 0.25 - 0.5 mg/day for 4 - 6 months. 
Colchicine 1 mg/day was used by (Adler 1998, Brucato 2000, Scardapane 2012 and Picco 2014, 
Peterlana 2005, Blasco 2006) for 6 months.  Scardapane 2012 and Brucato 2013 used 1mg - 1.5 
mg/day. Brucato 2013 also used 0.5mg / day for children less than 5 years. Raatika 2003 used a 
colchicine dose of up to 2 mg/day. 
DISCUSSION 
Colchicine is an established treatment for pericarditis in adults 6±9,W¶VHIficacy to 
reduces recurrences and help relieving symptoms has been proven in a number of 
RCTs 24±29. However, no RCT has been carried out in children 30 and there are no 
ongoing trials. We estimate that a RCT with 82 children is needed to detect the same 
pericarditis recurrence risk reduction as in adults (for 5% significance level and 80% 
power). 
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This systematic review shows that the evidence on colchicine in children is scarce, of 
poor quality and contradictory. The largest case series from 2013 14 has still not been 
published as a full text. One case series 14 and four case-reports 4,15±17 including 74 
children were in favour of using colchicine to prevent further pericarditis recurrences. 
These children had mainly an idiopathic pericarditis. On the other hand, one case series 
13
 and five case reports 18±22 including 12 children showed that colchicine did not 
prevent recurrences. Three of these studies were in children with post-pericardiotomy 
syndrome 13,20,21 . Two  studies 18,19 reported children with pericarditis resistant to 
colchicine but responded to the use of interleukin-1b receptor antagonist (anakinra).  
Studies reported that colchicine was well tolerated in children although the small 
number of included children might not be representative. It is noted that colchicine is 
not licensed in either the USA or Europe for the use in pericarditis31. 
LIMITATIONS 
Very little is reported on the use of colchicine in children in the medical literature. Included 
studies are case series and case reports only, therefore the conclusions of this review are based 
on low quality evidence. Two articles were only available as abstracts 14,17. 
Nine of the twelve included studies were reported from centres in the Mediterranean region 
(Italy, Spain, Lebanon and Israel) 4,14±16,18±22. This is similar to the situation in adult studies 
where all randomized controlled trials of colchicine in pericarditis were done in Italy 31.  It is 
possible that the findings may not apply to groups from other climates or geographical locations. 
Two studies reported pre- and post- colchicine recurrence rate to report colchicine efficacy in 
preventing recurrences 13,14. However, this conclusion is not appropriate as there was no control 
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group and it was not possible to tell what the recurrence rate in the same population would have 
been without colchicine.  
 
CONCLUSIONS 
The available literature suggests that colchicine might be effective in preventing recurrences in 
children with idiopathic pericarditis, however the quality of evidence is very low.  
Taking into account that colchicine is cheap to produce and effective in adults, it is important 
that its efficacy in children with pericarditis is tested further in the form of large double-blind 
randomised controlled trials. 
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"What is already known on this topic" 
Two in every thousand hospitalized children experience episodes of pericarditis. Recurrent 
episodes can occur in up to 30% of the affected children, severely impairing their quality of life. 
Colchicine has been shown to be effective in adults. 
 
"What this study adds" 
There is need for large double-blind randomised controlled trials is needed to establish the 
efficacy of colchicine in children with pericarditis   
14 
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Study 
Type 
Children 
on 
Colchicine 
Type of 
Pericarditis 
Age 
(years) 
Gender 
Follow 
up 
(months) 
Colchicine 
Dose 
Response to 
colchicine 
Adler 1998 
Case 
report 
1 Idiopathic  2  female 6  
1 mg/day 
for 6 
months 
No 
recurrences 
Blasco 
2006 
Case 
report 
1 
Post-
pericardiotomy  
12  male 24  1 mg/day 
Further 
recurrences 
Brucato 
2000 
Case 
report 
1 Idiopathic  14  male 29  
1 mg/day 
for 6 
months 
No 
recurrences 
Brucato 
2013 
Case 
series 
67 
87% idiopathic 
and 9% post-
pericardiotomy  
13 
(range 1 
- 17) 
62% 
male 
60 (6 -
360) 
0.5- 1.5 
mg/day  
Reduced 
Recurrences 
Del Fresno 
2013 
Case 
reports 
2 
Post- 
pericardiotomy  
4  
male 
and 
female 
24  
0.5mg/day 
for 4 
months 
Further 
recurrences 
Jurko 2002 
Case 
reports 
2 Idiopathic  
not 
reported 
not 
reported 
9 and 12  
not 
reported 
No 
recurrences 
Peterlana 
2005 
Case 
report 
1 Idiopathic  11  male 60 1 mg/day  
Further 
recurrences 
Picco 2009 
Case 
reports 
3 Idiopathic  
12, 13 
and 14  
1 male, 
2 female 
6  
1 mg/day 
for 6 
months 
Further 
recurrences 
Raatikka 
2003 
Case-
series 
4 
Post-
pericardiotomy  
8, 9, 12 
and 15  
3 males, 
1 female 
96p (48 - 
192) 
0.5- 2 
mg/day for 
6 months 
Further 
recurrences 
Scardapane 
2012 
Case 
report 
1 Idiopathic  11  male 24  
1 mg/day 
for 6 
months 
Further 
recurrences 
Yazigi 1998 
 
Case 
reports 
3 Idiopathic  
4, 5 and 
14  
male 17 - 24  
0.25 - 0.5 
mg/day for 
6 months 
No 
recurrences 
 
Table 1 Study Characteristics 
